- Home
- TSI vs FDMT Comparison
TSI vs FDMT Comparison
Compare TSI & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSI
- FDMT
- Stock Information
- Founded
- TSI 1987
- FDMT 2013
- Country
- TSI United States
- FDMT United States
- Employees
- TSI N/A
- FDMT N/A
- Industry
- TSI Investment Managers
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- TSI Finance
- FDMT Health Care
- Exchange
- TSI Nasdaq
- FDMT Nasdaq
- Market Cap
- TSI 236.5M
- FDMT 192.2M
- IPO Year
- TSI N/A
- FDMT 2020
- Fundamental
- Price
- TSI $4.99
- FDMT $7.09
- Analyst Decision
- TSI
- FDMT Buy
- Analyst Count
- TSI 0
- FDMT 9
- Target Price
- TSI N/A
- FDMT $30.63
- AVG Volume (30 Days)
- TSI 106.8K
- FDMT 750.8K
- Earning Date
- TSI 01-01-0001
- FDMT 08-11-2025
- Dividend Yield
- TSI 7.46%
- FDMT N/A
- EPS Growth
- TSI N/A
- FDMT N/A
- EPS
- TSI N/A
- FDMT N/A
- Revenue
- TSI N/A
- FDMT $33,000.00
- Revenue This Year
- TSI N/A
- FDMT $9,921.62
- Revenue Next Year
- TSI N/A
- FDMT N/A
- P/E Ratio
- TSI N/A
- FDMT N/A
- Revenue Growth
- TSI N/A
- FDMT N/A
- 52 Week Low
- TSI $4.48
- FDMT $2.24
- 52 Week High
- TSI $4.87
- FDMT $17.41
- Technical
- Relative Strength Index (RSI)
- TSI 67.76
- FDMT 63.07
- Support Level
- TSI $4.90
- FDMT $6.09
- Resistance Level
- TSI $4.94
- FDMT $7.33
- Average True Range (ATR)
- TSI 0.03
- FDMT 0.50
- MACD
- TSI 0.01
- FDMT -0.03
- Stochastic Oscillator
- TSI 92.59
- FDMT 83.22
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.